

Dialysis Event Surveillance Form

*required for saving

Patient Information		
Facility ID: *Patient ID: Secondary ID #: Patient Name, Last: *Sex: F-Female M-Male	Event ID #: Social Security #: Medicare #: First: Middle: *Date of Birth:	
Race (Select all that apply): American Indian or Alaska Native Asian Black or African American Middle Eastern or North African Native Hawaiian or Pacific Islander White Unknown Declined to respond Ethnicity: Hispanic or Latino Not Hispanic or Latino Unknown Declined to respond		
Event Information		
*Event Type: DE – Dialysis Event *Date of Event: *Location: *Was the patient admitted/readmitted to the dialysis facility on this dialysis event date? <input type="checkbox"/> Yes <input type="checkbox"/> No *Transient Patient <input type="checkbox"/> Yes <input type="checkbox"/> No		
Risk Factors		
*All Vascular Access Types Present: (check all that apply) Access placement date (mm/yyyy):		
<input type="checkbox"/> Fistula Buttonhole? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Graft <input type="checkbox"/> Tunneled central line <input type="checkbox"/> Non-tunneled central line <input type="checkbox"/> Other vascular access device	____/____/____ ____/____/____ ____/____/____ ____/____/____ ____/____/____	<input type="checkbox"/> Unknown <input type="checkbox"/> Unknown <input type="checkbox"/> Unknown <input type="checkbox"/> Unknown <input type="checkbox"/> Unknown
Is this a catheter-graft hybrid? <input type="checkbox"/> Yes <input type="checkbox"/> No Vascular access comment: _____		
*Access used for dialysis at the time of the event: (if more than one access was used for the dialysis treatment, please indicate the access with the higher risk of infection)		
<input type="checkbox"/> Fistula <input type="checkbox"/> Graft <input type="checkbox"/> Tunneled central line	<input type="checkbox"/> Non-tunneled central line <input type="checkbox"/> Other vascular access device <input type="checkbox"/> Catheter-Graft hybrid	
Event Details		
*Specify Dialysis Event: (check at least one)		
<input type="checkbox"/> IV antimicrobial start		
*Date of IV antimicrobial start:		
*Was vancomycin the antimicrobial used for this start? <input type="checkbox"/> Yes <input type="checkbox"/> No *Was this a new outpatient dialysis facility start or a continuation of a course initiated outside of the dialysis facility?		

Dialysis Event Surveillance Form

☐ New antimicrobial start

☐ Continuation of antimicrobial

*If new antimicrobial start, was a blood sample collected for culture? ☐ Yes ☐ No

☐ **Positive blood culture**

*Date of Positive blood culture: _____

(*specify organism and antimicrobial susceptibilities on pages 2-3)

* What is the suspected source of the organism or organisms identified on the positive blood culture?

☐ Vascular access

☐ A source other than the vascular access

☐ Contamination

☐ Uncertain

*Where was this positive blood culture collected?

☐ Dialysis clinic

☐ Hospital (on the day of or the day following admission) or E.D.

☐ Other location

☐ **Pus, redness, or increased swelling at vascular access site**

*Date of pus, redness, and increased swelling: _____

*Check the access site(s) with pus, redness, or increased swelling:

☐ Fistula

☐ Graft

☐ Tunneled

☐ Non-tunneled central line

☐ Other vascular access device

☐ Catheter-Graft

central line

Hybrid

*Specify Problem(s): (check one or more)

☐ Fever $\geq 37.8^{\circ}\text{C}$ (100°F) oral

☐ Chills or rigors

☐ Drop in blood pressure

☐ Wound (NOT related to vascular access) with pus or increased redness

☐ Urinary tract infection

☐ Cellulitis (skin redness, heat, or pain without open wound)

☐ Pneumonia or respiratory infection

☐ Other problem (specify): _____

☐ None

*Specify Outcomes:

Loss of vascular

☐ Yes

☐ No

☐ Unknown

Hospitalization

☐ Yes

☐ No

☐ Unknown

Death

☐ Yes

☐ No

☐ Unknown

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

Public reporting burden of this collection of information is estimated to average 50 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering, and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS H21-8, Atlanta, GA 30333, ATTN: PRA (0920-0666). CDC 57.502 (Front) Rev 10, v8.6

Dialysis Event Surveillance Form

Pathogen #	Gram-positive Organisms								
_____	<i>Staphylococcus coagulase-negative</i> (specify species if available): _____		VANC S I R N		CEFOX/OX S R N				
_____	____ <i>Enterococcus faecium</i> ____ <i>Enterococcus faecalis</i> ____ <i>Enterococcus</i> spp. (Only those not identified to the species level)		DAPTO S S-DD N S N		GENTHL ⁵ S R N		LNZ S I R N	VANC S I R N	
_____	<i>Staphylococcus aureus</i>		CIPRO/LEVO/MOXI S I R N	CLIND S I R N	DAPTO S N S N	DOXY/MINO S I R N	ERYTH S I R N	GENT S I R N	LNZ S R N
			OX/CEFOX/METH S I R N	RIF S I R N	TETRA S I R N	TIG S N S N	TMZ S I R N	VANC S I R N	CEFTAR S S-DD I R
Pathogen #	Gram-negative Organisms								
_____	<i>Acinetobacter</i> (specify species) _____	AMK S I R N	AMPSUL S I R N	AZT S I R N	CEFEP S I R N	CEFTAZ/CEFOT/CEFTRX S I R N		CIPRO/LEVO S I R N	COL/PB S I R N
		GENT S I R N	IMI S I R N	MERO/DORI S I R N	PIP/PIPTAZ S I R N	TETRA/DOXY/MINO S I R N			
		TMZ S I R N	TOBRA S I R N						
_____	<i>Escherichia coli</i>	AMK S I R N	AMP S I R N	AMPSUL/AMXCLV S I R N	AZT S I R N	CEFAZ S I R N	CEFEP S I/S-DDRN	CEFOT/CEFTRX S I R N	
		CEFTAZ S I R N	CEFUR S I R N	CEFOX/CTET S I R N	CEFTAVI S R N	CEFTOTAZ S I R N	CIPRO/LEVO/MOXI S I R N	COL/PB [†] S I R N	
		ERTA S I R N	GENT S I R N	IMI S I R N	MERO/DORI S I R N	PIPTAZ S I R N	TETRA/DOXY/MINO S I R N		
		TIG S I R N	TMZ S I R N	TOBRA S I R N	IMIREL S I R N	MERVAB S I R N			
_____	<i>Enterobacter</i> (specify species) _____	AMK S I R N	AMP S I R N	AMPSUL/AMXCLV S I R N	AZT S I R N	CEFAZ S I R N	CEFEP S I/S-DDRN	CEFOT/CEFTRX S I R N	
		CEFTAZ S I R N	CEFUR S I R N	CEFOX/CTET S I R N	CIPRO/LEVO/MOXI S I R N	COL/PB S I R N	CEFTAVI S R N		
		ERTA S I R N	GENT S I R N	IMI S I R N	MERO/DORI S I R N	PIPTAZ S I R N	TETRA/DOXY/MINO S I R N		
		TIG S I R N	TMZ S I R N	TOBRA S I R N	CEFTOTAZ S I R N	IMIREL S I R N	MERVAB S I R N		
_____	<i>Klebsiella pneumonia</i>	AMK S I R N	AMP S I R N	AMPSUL/AMXCLV S I R N	AZT S I R N	CEFAZ S I R N	CEFEP S I/S-DDRN	CEFOT/CEFTRX S I R N	

Dialysis Event Surveillance Form

_____ <i>Klebsiella oxytoca</i>	CEFTAZ SIR N	CEFUR SIR N	CEFOX/CTET SIR N	CIPRO/LEVO/MOXI SIR N	COL/PB* SIR N	CEFTAVI SR N
_____ <i>Klebsiella aerogenes</i>	ERTA SIR N	GENT SIR N	IMI SIR N	MERO/DORI SIR N	PIPTAZ SIR N	TETRA/DOXY/MINO SIR N
	TIG SIR N	TMZ SIR N	TOBRA SIR N	CEFTOTAZ SIR N	IMIREL SIR N	MERVAB SIR N

Pathogen #	Gram-negative Organisms									
_____	<i>Pseudomonas aeruginosa</i>	AMK SIR N	AZT SIR N	CEFEP SIR N	CEFTAZ SIR N	CIPRO/LEVO SIR N	COL/PB SIR N	GENT SIR N		
		IMI SIR N	MERO/DORI SIR N		PIP/PIPT SIR N	CEFTAVI SR N	TOBRA SIR N	CEFTOTAZ SIR N		
Pathogen #	Fungal Organisms									
_____	<i>Candida</i> (specify species if available)	ANID SIR N	CASPO SNS N	FLUCO SS-DD R N	FLUCY SIR N	ITRA SS-DD R N	MICA SNS N	VORI SS-DD R N		
Pathogen #	Other Organisms									
_____	Organism 1 (specify) _____	_____ D rug 1 SIR N	Drug 2 SIR N	Drug 3 SIR N	Drug 4 SIR N	_____ D rug 5 SIR N	Drug 6 SIR N	Drug 7 SIR N	Drug 8 SIR N	Drug 9 SIR N
_____	Organism 1 (specify) _____	_____ D rug 1 SIR N	Drug 2 SIR N	Drug 3 SIR N	Drug 4 SIR N	_____ D rug 5 SIR N	Drug 6 SIR N	Drug 7 SIR N	Drug 8 SIR N	Drug 9 SIR N
_____	Organism 1 (specify) _____	_____ D rug 1 SIR N	Drug 2 SIR N	Drug 3 SIR N	Drug 4 SIR N	_____ D rug 5 SIR N	Drug 6 SIR N	Drug 7 SIR N	Drug 8 SIR N	Drug 9 SIR N

Dialysis Event Surveillance Form

Result Codes

S = Susceptible I = Intermediate R = Resistant NS = Non-susceptible S-DD = Susceptible-dose dependent N = Not tested

§ GENTHL results: S = Susceptible/Synergistic and R = Resistant/Not Synergistic

† Clinical breakpoints have not been set by FDA or CLSI, Sensitive and Resistant designations should be based upon epidemiological cutoffs of Sensitive MIC ≤ 2 and Resistant MIC ≥ 4

Drug Codes:

AMK = amikacin	CEFTOTAZ =	FLUCY = flucytosine	OX = oxacillin
AMP = ampicillin	ceftolozane/tazobactam	GENT = gentamicin	PB = polymyxin B
AMPSUL = ampicillin/sulbactam	CEFTRX = ceftriaxone	GENTHL = gentamicin –high level test	PIP = piperacillin
AMXCLV = amoxicillin/clavulanic acid	CEFUR = cefuroxime	IMI = imipenem	PIPTAZ = piperacillin/tazobactam
ANID = anidulafungin	CTET = cefotetan	IMIREL = imipenem/relebactam	RIF = rifampin
AZT = aztreonam	CIPRO = ciprofloxacin	ITRA = itraconazole	TETRA = tetracycline
CASPO = caspofungin	CLIND = clindamycin	LEVO = levofloxacin	TIG = tigecycline
CEFAZ = cefazolin	COL = colistin	LNZ = linezolid	TMZ =
CEFEP = cefepime	DAPTO = daptomycin	MERO = meropenem	trimethoprim/sulfamethoxazole
CEFOT = cefotaxime	DORI = doripenem	MERVAB = meropenem/vaborbactam	TOBRA = tobramycin
CEFOX = ceftaxime	DOXY = doxycycline	METH = methicillin	
CEFTAR = Ceftaroline	ERTA = ertapenem	MICA = micafungin	VANC = vancomycin
CEFTAVI = ceftazidime/avibactam	ERYTH = erythromycin	MINO = minocycline	VORI = voriconazole
CEFTAZ = ceftazidime	FLUCO = fluconazole	MOXI = moxifloxacin	

Custom Fields

Label	Label
<hr/> <hr/> <hr/> <hr/> <hr/> <hr/> <hr/> <hr/>	<hr/> <hr/> <hr/> <hr/> <hr/> <hr/> <hr/> <hr/>

Comments